Mycophenolate vs steroids for alcoholic hepatitis
Treatments studied
Part of Digestive system clinical trials.
This trial compares two treatments for alcoholic hepatitis: mycophenolate mofetil (an immune-suppressing drug) and steroids. It aims to find which one works better for people with moderate to severe liver inflammation, and may offer a new option for those who cannot take steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have alcoholic hepatitis (liver inflammation caused by heavy drinking) confirmed by a doctor.
- Your MELD score (a measure of how severe your liver disease is) is between 20 and 35.
- You are willing to come back for follow-up visits.
- You do not have cancer, hepatitis B, HIV, or severe organ failure, and are not critically ill in the ICU.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a short course of steroids (anti-inflammatory medication) can help people with severe alcohol-associated hepatitis. It aims to see if this treatment improves liver function and survival.
This trial tests whether giving corticosteroids for a longer time, or adding a medicine called N-acetylcysteine, can help people with severe alcoholic hepatitis. It is for patients who have been drinking heavily and recently developed jaundice.
This early-phase study is testing a treatment approach for people with alcoholic hepatitis (liver inflammation caused by heavy alcohol use). It may help by improving liver function and outcomes in people who meet specific lab and health criteria.
This trial tests whether fecal microbiota transplantation (a controlled transfer of stool bacteria) is safe in people with severe alcoholic hepatitis. It aims to see if the treatment is tolerable and what risks may come with it, in addition to watching how liver illness changes.
This study tests whether adding N-acetylcysteine to standard treatment helps people with severe alcoholic hepatitis. It may improve liver outcomes, especially for those with a high Maddrey score.
This study tests a new drug called MRG-001 to see if it helps people with alcoholic hepatitis. The trial is looking for patients who have severe alcoholic hepatitis (with jaundice starting in the last 8 weeks) and have been drinking heavily for at least 6 months.
Hear when a new Alcoholic Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.